Hearing loss in adult patients with Fabry disease treated with enzyme replacement therapy
- 14 November 2014
- journal article
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 38 (2) , 351-358
Abstract
Introduction: Data on prevalence, natural history, and effect of enzyme replacement therapy (ERT) on hearing loss (HL) in Fabry disease (FD) are scarce.Methods: This is a retrospective study with cross‐sectional and longitudinal analyses. Low and high‐frequency HL in the Dutch FD cohort was studied in four groups: classical and non‐classical FD patients with or without ERT. To study effects of ERT, longitudinal data, corrected for age and gender according to ISO‐1999 guidelines, were analyzed with mixed models.Results: In the cross‐sectional analysis, 107 FD patients (41 males), median age 47.6 years (18.8–80.6) were analyzed. At baseline, i.e., before start of ERT, HL was present in 18 patients (16.8 %), of whom four had bilateral sensorineural HL. HL was more often present in patients with the classical phenotype than non‐classical patients (p < 0.01). Likewise, males had more often HL than females. Compared to the general population, FD patients show a median HL of 8.2 dB at low frequencies (p < 0.01) and 29.5 dB at ultra‐high frequencies (p < 0.01). Longitudinal analyses (n = 91) revealed that ERT treated patients show a similar rate of decline, not significantly different from healthy controls.Conclusion: Adult FD patients, especially classical affected males, show impaired hearing. Longitudinal analyses during ERT in these patients demonstrates a decline of HL similar to healthy controls, but HL present before initiation of therapy cannot be reversed. Whether early therapy can prevent hearing loss is unknown.Keywords
This publication has 34 references indexed in Scilit:
- Long‐term outcome of enzyme‐replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complicationsJournal of Internal Medicine, 2013
- Long term enzyme replacement therapy for Fabry disease: effectiveness on kidney, heart and brainOrphanet Journal of Rare Diseases, 2013
- Agalsidase beta treatment is associated with improved quality of life in patients with Fabry disease: Findings from the Fabry RegistryGenetics in Medicine, 2010
- Inner ear pathology of alpha-galactosidase A deficient mice, a model of Fabry diseaseAuris Nasus Larynx, 2010
- Elevated globotriaosylsphingosine is a hallmark of Fabry diseaseProceedings of the National Academy of Sciences, 2008
- Treatment of Fabry Disease: Outcome of a Comparative Trial with Agalsidase Alfa or Beta at a Dose of 0.2 mg/kgPLOS ONE, 2007
- Neuropathic and cerebrovascular correlates of hearing loss in Fabry diseaseBrain, 2006
- Hearing loss in Fabry disease: data from the Fabry Outcome SurveyEuropean Journal of Clinical Investigation, 2006
- Hearing threshold levels for an otologically unscreened, non-occupationally noise-exposed population in Sweden: Umbrales auditivos en una población no estudiada, sin exposición a ruido ocupacional en SueciaInternational Journal of Audiology, 2002
- The Role of High-Frequency Audiometry in Early Detection of OtotoxicityInternational Journal of Audiology, 1985